Verseon Corp. announced this week that it plans on unveiling new pre-clinical results in the form of a poster that will feature brand-new data for oral anticoagulant drug candidates currently in development.
The novel class of candidates currently represented by Verseon are extremely selective direct thrombin inhibitors (DTIs) with greater pre-clinical bleeding risk profiles than the existing new oral anticoagulants (NOACs). The data for the promising anticoagulants will be revealed at the third International Conference on Heart & Brain (ICHB) in Paris on Feb. 25.
Verseon is a technological-based pharmaceutical company that utilizes a patented computational platform to discover new drugs that enable it to invent innovative therapeutics for medical needs that have not yet been addressed. Verseon’s new class of DTIs, which are very potent and highly selective, has shown outstanding results in pre-clinical effectiveness studies. The DTIs also show pharmacokinetic properties that make them suitable to be administered orally.
The information that will be presented at the ICHB will provide data from a wide-ranging pre-clinical thrombosis model that will provide additional confirmation of the efficiency of the new drug candidates. Verseon has said that as its anticoagulant products continue to deliver positive results during the progression of the program.